Remy Luthringer, PhD
President and Chief Executive Officer
Dr. Remy Luthringer has been involved in the development of more than 150 active molecules for clinical trials in the central nervous system. Dr. Luthringer served as Chief Medical Officer for Index Ventures, with a focus on investments in healthcare infrastructure. He was also the head of the FORENAP Institute for Research in Neurosciences and Neuropsychiatry in France. Dr. Luthringer has extensive experience in clinical psychiatric practice and holds a PhD in neurosciences and clinical pharmacology.
Geoff Race, FCMA, MBA
Executive Vice President, Chief Financial Officer and Chief Business Officer
Prior to being named as Minerva Neurosciences' CFO and Chief Business Officer, Mr. Race served as a consultant for the development of MIN-101 and MIN-117. He has previously served as Chief Executive Officer of Funxional Therapeutics Ltd., the lead program of which (FX125L) was acquired by Boehringer Ingelheim in 2012. He also served as Chief Financial Officer at PanGenetics B.V. He is a Fellow of the Chartered Institute of Management Accountants and earned his MBA from Durham University Business School.
Michael Davidson, M.D.
Chief Medical Officer
Dr. Davidson has extensive experience in the research and development of drugs to treat diseases of the central nervous system. He has been a consultant for a number of pharmaceutical and biotechnology companies, and is a board member and reviewer for several professional organizations and neuroscience and psychiatry publications. Dr. Davidson has received the Neuroscience Award from the European College of Neuropsychopharmacology and from the International College of Neuropsychopharmacology. He is the recipient of over 50 research grants and has published over 300 articles primarily in peer reviewed journals in the areas of schizophrenia and Alzheimer’s disease.
Senior Vice President and Chief Operating Officer
Joe Reilly was most recently Vice President, Head of Commercial Strategy and Operations at Genzyme Corporation. In more than a decade at Genzyme, he also served as Vice President of Global Business Operations, Vice President of Commercial Operations and Vice President of Finance in the Rare Diseases Division. Joe holds a BS and MS in Finance from Boston College.
Senior Vice President and Chief Accounting Officer
Fred Ahlholm was most recently Vice President of Finance and Chief Accounting Officer for Amarin Corporation plc, where he helped direct the growth of the company from a small clinical-stage drug developer into a commercial enterprise of more than 400 employees. Fred is a CPA and earned his BBA at the University of Notre Dame.
Senior Vice President, General Counsel and Secretary
Mark Levine has extensive experience counseling companies on general corporate matters, complex commercial transactions, mergers and acquisitions, securities law, corporate governance and regulatory compliance. Prior to joining Minerva Neurosciences in 2014, he served in senior legal positions at athenahealth, Inc., Clinical Data, Inc., Wheelabrator Technologies Inc., and Xpedior Incorporated. He holds a bachelor of arts degree from Binghamton University, SUNY, and a juris doctor degree from Washington University School of Law in St. Louis.